Cargando…

P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS

Detalles Bibliográficos
Autores principales:	Sekeres, Mikkael, Santini, Valeria, Díez Campelo, María, S. Komrokji, Rami, Fenaux, Pierre, Robert Savona, Michael, Madanat, Yazan, Valcárcel, David, Illmer, Thomas, Jonášová, Anna, Belohlavkova, Petra, Regnault, Antoine, Creel, Kristin, Sengupta, Nishan, Sherman, Laurie, Berry, Tymara, Dougherty, Souria, Shah, Sheetal, Sun, Libo, Wan, Ying, Huang, Fei, Ikin, Annat, Navada, Shyamala, Feller, Faye, M. Zeidan, Amer, Platzbecker, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429194/ http://dx.doi.org/10.1097/01.HS9.0000969832.59030.29

Ejemplares similares

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Santini, Valeria, et al.
Publicado: (2023)

PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
por: Kuykendall, Andrew, et al.
Publicado: (2023)

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)
por: Mascarenhas, John, et al.
Publicado: (2023)

Evaluation of IMERG and ERA5 precipitation products over the Mongolian Plateau
por: Xin, Ying, et al.
Publicado: (2022)

A NEW MARAGLAS, D.E.R.® 732, EMBEDMENT FOR ELECTRON MICROSCOPY
por: Erlandson, Robert A.
Publicado: (1964)

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
por: Leibundgut, Elisabeth Oppliger, et al.
Publicado: (2020)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
por: Tefferi, A, et al.
Publicado: (2016)

Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton
por: MENDER, ILGEN, et al.
Publicado: (2013)

732 Economic and Environmental Benefits of Telemedicine Expansion
por: Miotke, Sam, et al.
Publicado: (2023)

The evaluation of IMERG and ERA5-Land daily precipitation over China with considering the influence of gauge data bias
por: Xie, Wenhao, et al.
Publicado: (2022)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma
por: Wu, Xuping, et al.
Publicado: (2017)

CCNP Wireless 642-732 CUWSS quick reference
por: Henry, Jerome
Publicado: (2012)

732. Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism
por: Nguyen, Minh-Vu Hoang, et al.
Publicado: (2019)

Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells
por: Burchett, Katrina M., et al.
Publicado: (2014)

Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors
por: Baerlocher, Gabriela M., et al.
Publicado: (2020)

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
por: Chapuis, Nicolas, et al.
Publicado: (2023)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Panniculectomy Outcomes by Body Mass Index: an Analysis of 12,732 Cases
por: Cadwell, Joshua B., et al.
Publicado: (2021)

The Alzheimer Amyloid Precursor Protein (APP) and Fe65, an APP-Binding Protein, Regulate Cell Movement
por: Sabo, Shasta L., et al.
Publicado: (2001)

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
por: Barwe, Sonali P., et al.
Publicado: (2022)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

732. Description of Diagnoses and Antibiotic Management of Otitis Media and Otitis Externa in Adults
por: Pontefract, Benjamin, et al.
Publicado: (2018)

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
por: Nazha, Aziz, et al.
Publicado: (2017)

Des faisceaux de neutrinos ont parcouru 732 km sous les Alpes
Publicado: (2006)

Des faisceaux de neutrinos ont parcouru 732km sous les Alpes
Publicado: (2007)

M7.3.2: Dipole Nb$_{3}$Sn model magnet finished
por: Pietrowicz, S, et al.
Publicado: (2011)

732 Predictors of Cardiac Implantable Electronic Device Infection in Patients with Staphylococcus Aureus Bacteremia
por: Elmalik, Hassan, et al.
Publicado: (2014)

The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA
por: Liu, Si-Jin, et al.
Publicado: (2007)

Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models
por: Fischer-Mertens, Janina, et al.
Publicado: (2022)

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
por: Mascarenhas, J., et al.
Publicado: (2022)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
por: Garcia-Manero, Guillermo, et al.
Publicado: (2022)

Corrigendum to: “FreeSurfer subcortical normative data” [Data in Brief 9 (2016) 732–736]
por: Potvin, Olivier, et al.
Publicado: (2019)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oq0ql90p0ueru02lvoknjju65e